Milestone Pharmaceuticals Inc. Common Shares
MISTMilestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cardiovascular diseases and acute care conditions. Founded to address unmet medical needs, the company leverages its expertise in clinical research and drug development to bring novel treatments to market. Its pipeline includes products aimed at improving patient outcomes in areas such as arrhythmias and other acute cardiovascular events.
Company News
Milestone Pharmaceuticals received FDA approval for CARDAMYST, the first self-administered nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults, offering a novel at-home treatment option for over 2 million Americans with this heart condition.
Milestone Pharmaceuticals presented clinical trial data for etripamil nasal spray, showing consistent efficacy and safety in treating paroxysmal supraventricular tachycardia (PSVT) across multiple studies, with a New Drug Application currently under FDA review.
Milestone Pharmaceuticals will present research data on etripamil, a potential treatment for paroxysmal supraventricular tachycardia, at the American Heart Association Scientific Sessions in New Orleans in November 2025.
A comprehensive market research report analyzing the Atrial Fibrillation pipeline, covering over 10 companies and 12+ pipeline drugs, highlighting emerging treatments, clinical trials, and key developments in managing cardiac arrhythmia.
Milestone Pharmaceuticals has initiated an underwritten public offering of common shares and warrants to raise funds for clinical development and commercial launch of etripamil, a treatment for paroxysmal supraventricular tachycardia (PSVT).
